| CHINESE | JAPANESE | KOREAN |
  Home         Investment Guide          News          Special Coverage          News in Retrospect          Contact Us
  Industries & Enterprises  | Tourism & Leisure  | Education & Schools  | Infrastructure & Ecology  | Life & Culture  | Authorities & Policies
 
  The Scholarly SIP with...
书香园区 (3).png
 
  2017 China Suzhou Cult...
创博会专题-03.png
 
  Spring Outing at Yangc...
春行半岛-03.png
 
  SIP accelerates to sha...
人工智能专题-03.png
 
  Enjoy the Spring in SIP
QQ图片20170410131338.png
 
 
Current Position: Home page > category report > Industries & Enterprises
  Print page Text size:  
 


New oral medicine against diabetes to enter clinic trial


The new Category I medicine developed by CGeneTech (Suzhou, China) Co Ltd for treatment of Type 2 diabetes has received approval for clinic trial, according to a recent announcement by SIP BioBAY.

Diabetes is currently a major threat to human health. According to International Diabetes Federation (IDF), there are more than 100 million diabetes patients in China.

The new medicine (CGT-8012) was developed based on new target points identified through 10-year clinic verification. It is safe, effective and does not cause fasting hypoglycemia or weight gain. Moreover, it is given orally. Therefore, it has caught great attention of the pharmaceutical industry in recent years.


May 8, 2017

 
 
   
 
  FEATURED VIDEOS  
     
   
  Suzhou Industrial Park Video  
  Watch